enflurane (Rx)Brand and Other Names:Ethrane, Compound 347

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

volatile liquid for inhalation

  • 250mL per bottle (99.9%)
more...

Anesthesia

Surgical anesthesia

  • Induction: 2-4.5% inspired concentrations produce surgical anesthesia within 7-10 min; administer with oxygen or combination of oxygen/nitrous oxide mixture
  • Maintenance: 0.5-3% inspired concentrations maintain surgical anesthesia; if added relaxation is required, supplemental with muscle relaxants; ventilate to maintain carbon dioxide tension in arterial blood between 35-45 mmHg

Cesarean Section

  • 0.5-1% as supplement to other general anesthetics

Analgesia

Vaginal delivery: 0.25-1% provides analgesia equivalent to that produced by 30-60% nitrous oxide

Safety and efficacy not established

Next

Interactions

Interaction Checker

enflurane and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Malignant hyperthermia

            Motor activity/seizures (with deep anesthesia or light anesthesia accompanied by hypocapnia)

            Hypotension

            Respiratory depression

            Hypoxia

            Arrhythmias

            Shivering

            Nausea

            Vomiting

            Increased WBCs

            Liver impairment, including hepatic failure (rare)

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity

            Seizure disorders

            Known or suspected genetic susceptibility to malignant hyperthermia

            Cautions

            Avoid hyperventilation to minimize possible CNS excitation

            Continuous blood pressure monitoring required; lighten administration if excessive BP decrease occurs (unless hypovolemic)

            Renal dysfunction is associated with serum fluoride levels >50 micromol/L

            Postoperative hepatitis reported

            Increased intracranial pressure may occur

            May trigger skeletal muscle hypermetabolic state leading to high oxygen demand and malignant hyperthermia

            Caution in patients considered more susceptible to cortical stimulation

            Decrease dose of neuromuscular blocker if coadministered (longer recovery when coadministered with enflurane compared with halothane or nitrous oxide)

            May decrease hepatic, renal, hepatic, and splenic blood flow

            Should not be used as a sole agent of induction in patients with ventricular dysfunction

            Perioperative Hyperkalemia

            • Inhaled anesthetics associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients postoperatively
            • Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable
            • Concomitant use of succinylcholine has been associated with most, but not all, of these cases
            • Elevated serum creatinine kinase levels and, in some cases, changes in urine consistent with myoglobinuria observed
            • Despite similar presentation to malignant hyperthermia, none of affected patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state
            • Early and aggressive intervention to treat hyperkalemia and resistant arrhythmias recommended
            • Evaluation for latent neuromuscular disease recomended
            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: Unknown whether distributed in breast milk, caution advised

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Inhalation anesthetic

            Pharmacokinetics

            Onset of action: 7-10 minutes

            Peak Plasma Concentration: Biotransformation results in low serum fluoride levels (average 15 micromol/L); can exceed 50 micromol/L if anesthesia >2 MAC hr

            Metabolism: Liver

            Excretion: Respiratory exhaled gases

            Pharmacogenomics

            Increased incidence of malignant hyperthermia with use of volatile anesthetics or depolarizing neuromuscular blockers in patients with gene mutations in ryanodine receptor (RYR1) or calcium channel alpha (1S)- subunit gene (CACNA1S)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.